GlassScriptPhysician profile
Minh N Dang
NPI 1629058441
$9,794.73
in general payments reported to CMS, 2019-2025
41 companies · $1,125 in 2025
The $1,125 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,379 · 2020: $1,986 · 2021: $1,535 · 2022: $514 · 2023: $1,060 · 2024: $1,196 · 2025: $1,125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,153 · Education: $227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,153.30 |
| Education | $227.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,914.01 | 2019-2025 | Skyrizi, Botox, Rinvoq |
| Mayne Pharma Commercial LLC | $994.56 | 2019-2021 | |
| Janssen Biotech, INC. | $838.31 | 2019-2025 | Tremfya, Simponi, Stelara |
| Lilly USA, LLC | $626.11 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $571.99 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $522.90 | 2019-2025 | Dupixent, Libtayo |
| Genentech USA, INC. | $521.99 | 2019-2022 | |
| Leo Pharma INC. | $506.90 | 2019-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $401.62 | 2019-2025 | Nemluvio, Dysport |
| Amgen INC. | $296.03 | 2019-2022 | |
| Genzyme Corporation | $287.28 | 2019-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $246.62 | 2019-2025 | Jublia, Arazlo, Siliq |
| Incyte Corporation | $178.68 | 2021-2025 | Opzelura |
| Dermavant Sciences, INC. | $161.87 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $155.12 | 2020-2025 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $126.47 | 2019-2021 | |
| Vyne Pharmaceuticals INC. | $124.69 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $122.06 | 2019-2025 | |
| Smith+Nephew, INC. | $121.55 | 2023-2024 | Collagenase Santyl, Grafix, Grafix Pl |
| Arcutis Biotherapeutics, INC. | $118.72 | 2023-2025 | Zoryve |
| Dermira, INC. | $112.33 | 2019-2021 | |
| Ucb, INC. | $98.78 | 2019-2025 | Bimzelx |
| Almirall LLC | $93.53 | 2019-2025 | Klisyri |
| E.R. Squibb & Sons, L.L.C. | $76.88 | 2022-2024 | Sotyktu |
| Journey Medical Corporation | $75.18 | 2019-2025 | |
| Scilex Pharmaceuticals INC. | $61.31 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $50.71 | 2019-2020 | |
| Biofrontera INC. | $42.69 | 2019 | |
| Hill Dermaceuticals, INC. | $41.89 | 2025 | Tolak |
| Dusa Pharmaceuticals, INC. | $39.16 | 2019 | |
| Celgene Corporation | $35.54 | 2019 | |
| Botanix Sb INC | $35.10 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $28.28 | 2025 | Ycanth |
| Allergan, INC. | $27.84 | 2019-2022 | |
| Organogenesis INC. | $27.40 | 2024 | |
| Mimedx Group, INC. | $25.47 | 2024 | |
| Kerecis Limited | $21.29 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Merck Sharp & Dohme LLC | $18.66 | 2019 | |
| Surgenex LLC | $17.71 | 2025 | Surgraft, Surmatrix, Pellograft |
| Emergent Biosolutions INC. | $15.07 | 2019 | |
| Taro Pharmaceuticals USA, INC. | $12.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Minh Dang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.